Clexio Biosciences

Focus: Clexio Biosciences is an Israeli biotech firm focused on neuropsychiatry and oncology therapeutics, currently in clinical-stage development with a modest pipeline.

Oncology Psychiatry

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Clexio Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Clexio Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CLE-100

Adjunctive Treatment of Major Depressive Disorder (MDD)

Phase 2

Clinical Trials (1)

NCT06340958A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder

Phase 2

Help build intelligence for Clexio Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to contribute to Phase 2 programs in high-need areas: MDD (adjunctive treatment) and notalgia paresthetica, both with limited existing therapies.
Early-stage biotech environment offers hands-on impact and rapid skill-building across clinical development and regulatory strategy.
Israel-based location provides access to a thriving biotech ecosystem and potential for cross-company networking and talent mobility.

Watch Out For

No active job openings currently listed, indicating limited near-term hiring or possible consolidation phase.
Pre-revenue stage with undisclosed funding creates uncertainty around runway, salary competitiveness, and long-term employment stability.

Generated by Claude from Clexio Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

CLE-100

Adjunctive Treatment of Major Depressive Disorder

Phase 2

Clinical Trials (1)

NCT04103892A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study

Phase 2

CLE-400

Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP)

Phase 2

Clinical Trials (1)

NCT06262607A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Top TAs: Dermatology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Dermatology

1 pipeline

Marketed

Pipeline